… We propose that therapeutic treatment with heparin/LMWH will interfere with several
pathological processes in COVID-19 patients, thereby increasing their survival rate. …

… opportunity for the treatment of COVID-19 disease by repurposing a long-serving medical
agent with an excellent history of clinical use, namely heparin. Heparin is best known as an …

… the effects of therapeutic heparin in hospitalized patients with COVID‐19. … heparin is
beneficial in moderately ill patients but not in severely ill patients hospitalized with COVID‐19…

… Clinical observations found that systemic symptoms caused by … of heparin, we illustrate
both the preclinical and clinical evidence that heparin therapy has multiple effects for COVID-19. …

… , mechanically ventilated patients who received systemic anti-coagulation during their
hospital course had a lower hospital mortality (adjusted HR of 0.86 per day, 95% confidence …

… that respiratory infection is also responsible for a systemic procoagulant activity,3-5 which
… this evidence, heparin has become a cornerstone of the treatment against COVID-19, along …

… Our findings are similar to those of Ayerbe et al, showing that heparin treatment was … with
COVID-19 admitted to 17 hospitals in Spain.[38] Additionally, focusing on LMWH therapy, …

… distress syndrome, empirical systemic anticoagulation significantly reduced venous … ,
the addition of heparin can have a favorable impact on progression of COVID-19 infection. …

… We randomly assigned moderately ill hospitalized ward patients admitted for Covid-19 with
elevated D-dimer level to therapeutic or prophylactic heparin. The primary outcome was a …

… In moderately ill patients with covid-19 and increased D-dimer levels admitted to hospital
wards, therapeutic heparin was not significantly associated with a reduction in the primary …